The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: First-year results from the Compliance of ARomatase Inhibitors AssessmenT In Daily practice through Educational approach (CARIATIDE) study

Breast

Volumn 23, Issue 4, 2014, Pages 393-399

  Neven, Patrick ^a   Markopoulos, Christos ^b   Tanner, Minna ^c   Marty, Michel ^d   Kreienberg, Rolf ^e   Atkins, Louise ^f   Franquet, Ann ^g   Gnant, Michael ^h   Neciosup, Silvia ⁱ   Tesarova, Petra ^j   Barni, Sandro ^k   Deschamp, Veronique ^l  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^j CHARLES UNIVERSITY   (Czech Republic)

^k TREVIGLIO HOSPITAL   (Italy)

^l ASTRAZENECA   (United Kingdom)

more..

Author keywords

Adherence; Breast cancer; Compliance; Endocrine therapy; Oncology; Persistence

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; LETROZOLE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; EARLY CANCER; FEMALE; FINLAND; HEALTH IMPACT ASSESSMENT; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; POSTMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SWEDEN; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; AGED; BREAST NEOPLASMS; CLINICAL TRIAL; LYMPH NODE DISSECTION; MASTECTOMY; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODE EXCISION; MASTECTOMY; MEDICATION ADHERENCE; MIDDLE AGED; NITRILES; PATIENT EDUCATION AS TOPIC; POSTMENOPAUSE; TRIAZOLES;

EID: 84902545429     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.02.009     Document Type: Article

References (35)

1. Aebi S., Davidson T., Gruber G., Cardoso F. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(Suppl.6):vi12-vi24.
2. Burstein H.J., Prestrud A.A., Seidenfeld J., Anderson H., Buchholz T.A., Davidson N.E., et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. JClin Oncol 2010, 28:3784-3796.
3. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thurlimann B., Senn H.J. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747.
4. Ward J.H. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?. Curr Opin Obstet Gynecol 2010, 22:51-55.
5. Banning M. Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care (Engl) 2012, 21:10-19.
6. Fontein D.B., Nortier J.W., Liefers G.J., Putter H., Meershoek-Klein K.E., van den Bosch J., et al. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial. Eur J Surg Oncol 2012, 38:110-117.
7. Ma A.M., Barone J., Wallis A.E., Wu N.J., Garcia L.B., Estabrook A., et al. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg 2008, 196:500-504.
8. Sedjo R.L., Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 2010, 125:191-200.
9. Hershman D.L., Shao T., Kushi L.H., Buono D., Tsai W.Y., Fehrenbacher L., et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2010, 126:529-537.
10. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010, 73:156-166.
11. Kirk M.C., Hudis C.A. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 2008, 8:155-161.
12. Cluze C., Rey D., Huiart L., BenDiane M.K., Bouhnik A.D., Berenger C., et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 2012, 23:882-890.
13. Wengstrom Y., Aapro M., Leto di Priolo S., Cannon H., Georgiou V. Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. Breast 2007, 16:462-468.
14. Hadji P., Blettner M., Harbeck N., Jackisch C., Luck H.J., Windemuth-Kieselbach C., et al. The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 2013, 24:1505-1512.
15. Yu K.D., Zhou Y., Liu G.Y., Li B., He P.Q., Zhang H.W., et al. Aprospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Breast Cancer Res Treat 2012, 134:307-313.
16. Waterhouse D.M., Calzone K.A., Mele C., Brenner D.E. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. JClin Oncol 1993, 11:1189-1197.
17. Partridge A.H., Wang P.S., Winer E.P., Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. JClin Oncol 2003, 21:602-606.
18. Partridge A.H., LaFountain A., Mayer E., Taylor B.S., Winer E., Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. JClin Oncol 2008, 26:556-562.
19. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9:45-53.
20. El Hasnaoui A., Vray M., Blin P., Nachit-Ouinekh F., Boureau F. Assessment of migraine severity using the MIGSEV scale: relationship to migraine features and quality of life. Cephalalgia 2004, 24:262-270.
21. Rodriguez L.V., Blander D.S., Dorey F., Raz S., Zimmern P. Discrepancy in patient and physician perception of patient's quality of life related to urinary symptoms. Urology 2003, 62:49-53.
22. Atkins L., Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 2006, 42:2271-2276.
23. Davidson B., Vogel V., Wickerham L. Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. JSupport Oncol 2007, 5:139-143.
24. Osterberg L., Blaschke T. Adherence to medication. NEngl J Med 2005, 353:487-497.
25. Rosenzweig M., Brufsky A., Rastogi P., Puhalla S., Simon J., Underwood S. The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity. Oncol Nurs Forum 2011, 38:85-89.
26. Kokko R., Hakama M., Holli K. Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Res Treat 2005, 93:255-260.
27. Cuzick J., Sestak I., Cella D., Fallowfield L. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008, 9:1143-1148.
28. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. JClin Oncol 2003, 21:2101-2109.
29. Hadji P., Jackisch C., Bolten W., Blettner M., Hindenburg H.J., Klein P., et al. COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol 2013, 24:1505-1512.
30. Coleman R.E., Bolten W.W., Lansdown M., Dale S., Jackisch C., Merkel D., et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 2008, 34:275-282.
31. Caro J.J., Speckman J.L. Existing treatment strategies: does noncompliance make a difference?. JHypertens Suppl 1998, 16:S31-S34.
32. Haynes R.B., Ackloo E., Sahota N., McDonald H.P., Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008, CD000011.
33. Horne R., Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. JPsychosom Res 1999, 47:555-567.
34. Clifford S., Barber N., Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the Necessity-Concerns Framework. JPsychosom Res 2008, 64:41-46.
35. Horne R., Weinman J., Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999, 14:1-24.